This study examines women with breast cancer and their oncologists' views on chemotherapy. It is not aimed at young women in particular; participant ages range from 20-79, with an average age of 62 years.
This study does not address impact on women with inherited mutations in breast cancer predisposing genes.
The population studied is restricted to estrogen receptor-positive, HER2-negative, early-stage breast cancer.
The study was not designed to look at patient outcomes based on their tumor test or treatment type. Rather this research was designed to study the information doctors use to make treatment recommendations.